Five nonoverlapping antigenic sites (sites I through V) of woodchuck hepatitis virus surface antigen were identified with competitive binding assays involving monoclonal antibodies. Site I contributed to cross-reactions among surface antigens of hepatitis B-like viruses infecting woodchucks, ground squirrels, and humans. At least three distinct sites (sites I, II, and III) are responsible for crossreactions between woodchuck and ground squirrel hepatitis virus surface antigens. Sites IV and V of woodchuck hepatitis virus surface antigen are not major cross-reactive sites, suggesting that these elicit virus-specific antibodies. There were no cross-reactions with duck hepatitis B virus surface antigen.
Five nonoverlapping antigenic sites (sites I through V) of woodchuck hepatitis virus surface antigen were identified with competitive binding assays involving monoclonal antibodies. Site I contributed to cross-reactions among surface antigens of hepatitis B-like viruses infecting woodchucks, ground squirrels, and humans. At least three distinct sites (sites I, II, and III) are responsible for crossreactions between woodchuck and ground squirrel hepatitis virus surface antigens. Sites IV and V of woodchuck hepatitis virus surface antigen are not major cross-reactive sites, suggesting that these elicit virus-specific antibodies. There were no cross-reactions with duck hepatitis B virus surface antigen.
Woodchucks (Marmota monax) are naturally infected by an hepatotropic DNA virus, or hepadnavirus (23) , that is morphologically and structurally similar to hepatitis B virus of humans (27, 28) . Infection of marmots by woodchuck hepatitis virus (WHV) has been viewed as a naturally occurring animal model for virusinduced liver disease and its long-term sequelae, which include chronic hepatitis and hepatocellular carcinoma (2, 21) . The surface antigen of these and other hepatitis B-like viruses is found mainly in the form of noninfectious subviral particles that circulate in the blood of infected hosts in vast excess of the virion (26) . The particles share antigenic determinants with viral coat proteins (12, 24) and are therefore useful in the preparation of subunit vaccines (9, 10, 19, 22, 29) . In the hepatitis B virus system, genetic variation in the hepatitis B surface antigen (HBsAg) can be detected with serum antibodies recognizing group (a) and subtype (dly, wir) antigenic determinants (1, 9, 15, 25) . In contrast, serological specificities corresponding to different surface antigenic determinants of WHV have not yet been identified. In the present study, we used monoclonal antibodies to identify five nonoverlapping antigenic domains of woodchuck hepatitis virus surface antigen (WHsAg). The five sites were delineated in competitive binding assays with monoclonal antibodies and were further characterized for their cross-reactivity MATERIALS AND METHODS MCABs. Monoclonal antibodies (MCABs) predefined by immunization of BALB/c mice with WHsAg have been described previously (4) . One antibody reacts with WHsAg, GSHsAg, and HBsAg (MCAB no. 101-2), several react with WHsAg and GSHsAg, and others react only with WHsAg. MCABs are herein identified by their primary clonal identification numbers and their antigenic site specificity (e.g., 101/I, 3/11, etc.; see below). Antibodies were partially purified from ascites fluids by ammonium sulfate salt precipitation and were radioiodinated by a solid-phase lactoperoxidase method (14) .
Antigens. The 22-nm form of WHsAg was isolated from plasma of WHV chronic carrier woodchucks by established ultracentrifugation procedures (9, 10) . Solid-phase antigen adsorbents and radioiodinated antigen (3, 4) were prepared with purified WHsAg obtained from two different woodchucks (no. 7 and 8, respectively; National Institute of Allergy and Infectious Diseases Animal Colony, Meloy Laboratories, Inc., Rockville, Md.). The standard WHsAg-positive serum was that obtained from woodchuck no. 8. A serum sample positive for GSHsAg was a gift of P. L. Marion and W. S. Robinson (5, 11, 17) . A serum sample positive for duck hepatitis B virus surface antigen was a gift of J. Summers (18) . Sera positive for various HBsAg subtypes were obtained from the Research Resources Branch of the National Institute of Allergy and Infectious Diseases (Bethesda, Md.). Standard control serum was obtained from a colony woodchuck that was negative for all markers of WHV infection. Normal human serum was obtained from the Site  Clone  I  II  III   IV   V  101  3  14  114  19  172  71  181  41  31  151  I  101  82  28  25  0  27  19  36  40  26  18  11  II  3  8  91  92  8  27  14  14  15  32  1  23  II  14  17  83  89  13  33  19  6  18  24  1  1  III  114  37  16  16  80  52  46  32  31  31  8  22  III  19  36  21  35  44  90  85  18  23  17  17  13  III  172  31  27  33  61  91  95  29  32  33  19  9  IV  71  14  25  27  14  29  3  76  87  32  11  12  IV  181  18  24  20  22  37  11  74  93  27 Table 1 ). To construct the matrix, antibodies were ordered so that strong reciprocal inhibition reactions fell on either side of the central diagonal. Three levels of competition inhibition reactions were discerned by histographic analysis (data not shown); these were qualitatively designed as strong, moderate, and low level (i.e., negligible). The mean percent inhibition (± standard error) for strong competition reactions was 86 ± 1% (n, 22; range, 74 to 95% inhibition). The mean for moderate competitions was 51 ± 3% inhibition (n, 5; range 44 to 61%); that for negligible competition was 20 ± 1% inhibition (n, 88; range, 0 to 35%). A few of the assays resulted in borderline competition between antibodies when tested in one direction (n, 6; range, 36 to 41%); however, the reciprocal test demonstrated little or no competition (e.g., 31/V ascites versus 1251-14/I1 and 14/II ascites versus 125I-31/V). In such cases, the average of reciprocal tests was always less than 35% inhibition, and thus the antibodies were considered mutually noncompetitive. One-way observations of this type could be explained if an antibody specific for one epitope was able at higher concentrations to interact weakly with a heterologous epitope or to induce partial allosteric changes elsewhere in the antigen. Weak reciprocal competition between antibody groups mapping to distinct sites could suggest either partial recognition phenomena or immediate proximity relationships between two sites.
Strong reciprocal inhibition reactions in CAB assays suggested that domains mapped by two or more MCABs are defined by steric inhibition between antibodies directed against the same epitope (or determinant) (sites II through V, Table 1 ). On the other hand, this level of inhibition need not imply that a given antigenic domain corresponds to a single determinant; that is, competition between two antibodies against two distinct epitopes may be strong if the determinants are spatially close together within a reactive domain. We noted that the reciprocal inhibition reactions between antibody 114 and antibodies 19 and 172 were consistently within the moderate range (site III, Table 1 ). This could suggest that the 114 determinant is distinct from the 19 and 172 epitope(s) although they are all spatially close enough to be resolved as a single domain by antibody competition. Other factors could also influence the relative strengths of reciprocal inhibition reactions, including the balance and affinities of labeled and unlabeled antibody species in the reaction mixture. Molecular size differences, as in immunoglobulin M (IgM) versus IgG competition, were not a complicating factor because the competing species were all of the same isotype (IgGl, K). Enhancement of antibody binding at distinct sites was not observed for any of the antibody combinations tested (16 (Table 2) . Thus, sites I, II, and III of WHsAg cross-react with GSHsAg, whereas sites IV and V are not major antigenic sites of GSHsAg (the latter being most likely WHsAg-specific sites). The same general pattern of detection was observed when these two antigens were assayed on site-specific immunoadsorbents followed by a probe with the 101 antibody; in this system some low-level reactivity of GSHsAg with the site IV and V immunoadsorbents was detected by the 101 probe (Table 3) . Such reactivity was only associated with assay of GSHsAg-postive serum at lower dilutions (Fig. 1) . Overall, the data clearly show site-specific antigenic differences between WHsAg and GSHsAg. HBsAg was detected with the site I immunoadsorbent-probe combination, but not with any of the others (Table 3) . These observations were further confirmed in double-antibody RIP assays against highly purified, 125I-HBsAg/ ad and /ay ligands; of the present antibodies, only the 101 antibody reacts with HBsAg in RIP (data not shown). In addition, HBsAg bound to HBsAg-specific monoclonal immunoadsorbents can be readily detected with the 101 probe at positive/negative ratios comparable to or greater than that given in TableTABLE 2 (Table 4) .
Except for such cases, specific blocking would occur at the level of the immunoadsorbent (see below). Whenever either antigen was prereacted with MCABs other than 101/I, the immune complexes were bound to a 101/I immunoadsorbent, and the antigens were detected at or near control levels with the 101/I probe (Table 4) . Thus, antibodies to sites II through V of WHsAg did not map to site I of WHsAg which is defined by the 101/I antibody (see also CAB assay in Table  1 ); the comparative immunocomplex mapping data in Table 4 indicate that domain I is distinct from other sites on GSHsAg also.
In keeping with this approach, we found that site II Table 4 . GSHsAg in positive serum at 1:125 dilutions was not consistently detected at significant levels when site IV and V immunoadsorbents were used to bind the antigen; however, WHsAg was readily detected in those assay systems (Table 4, Table 3 , Fig. 1F,  G, and H) . Therefore, only WHsAg was detected in the immunocomplex mapping of sites IV and V (Table 4 specific. The data suggests that up to three noncompeting antibodies can bind simultaneously to their respective antigenic sites on either antigen.
Enumeration and cross-reactivity of WHsAg domains. The five nonoverlapping antigenic domains of WHsAg are shown in Fig. 2A (adapted from Table 1 ). The clones producing the MCABs that define these sites were isolated independently from three different hybridization experiments (i.e., from three different mice immunized similarly [4] ). Different hybridomas defining up to four sites could be derived from the same mouse (Fig. 2B ). More importantly, hybridomas defining the same WHsAg site could be derived independently from different mice (Fig. 2B) . The probability of obtaining such antibody sets out of 11 antibodies would be low if WHsAg possessed a large number of nonoverlapping domains. This, coupled with the observation that five distinct sites could be defined by a total of only 11 antibodies, suggests that 22-nm WHsAg is characterized by repeat antigenic structure involving only a limited set of nonoverlapping antigenic specificities.
In a previous study we demonstrated at least three different determinants of WHsAg based on antigenic competition assays involving WHsAg, GSHsAg, HBsAg, and the present MCABs (4). Those results were adapted for comparison with RIA results obtained in the present study, and all are presented in Fig. 2B . The present analysis involves three distinct but related antigens. We cannot yet identify nonoverlapping epitopes within antigenic domains of WHsAg by using homologous variants (7, 31, 32) , because such variants have not yet been identified. However, the data do show that the five nonoverlapping antigenic domains of WHsAg identified in competitive antibody mapping exhibit characteristic specificity and cross-reactivity patterns in comparative analyses with related antigens ( Fig. 2A  and B) . The 101/I antibody defines a surface antigenic site that contributes to cross-reactions among the mammalian hepadnaviruses. It does not react with duck hepatitis B virus surface antigen, which is known to be antigenically distinct (18) . Regarding woodchuck and ground squirrel viruses, the results indicate that at least three analogous nonoverlapping antigenic sites contribute to moderate and strong cross-reactions between WHsAg and GSHsAg (sites I, II, and III; Fig. 2A and B ; Table 4 ). Antibodies reacting poorly with GSHsAg mapped to sites IV and V of WHsAg, suggesting that at least two nonoverlapping antigenic domains of WHsAg are involved in eliciting virus-specific antibodies. The present results do not rule out the possibility of eventually isolating strongly crossreactive antibodies that map competitively to sites IV and V of WHsAg, nor do they rule against the mapping of WHsAg-specific antibodies to sites characterized by cross-reactive antibodies (such as sites I, II, and III). These types 
DISCUSSION
The molecular relationship between MCAB cross-reactivity and shared antigenic determinants among mammalian hepadnaviruses is not yet fully understood. For example, differences in MCAB avidity for related surface antigens may result from partial antibody recognition of a similar epitope on heterologous antigens, or from differences in the copy number and distribution of an epitope on related subviral particles (or both). During our studies with WHsAg, we isolated the 101/I murine hybridoma, whose antibody clearly reacts with WHsAg and GSHsAg and also reacts significantly, but to a lesser extent, with HBsAg (4) (present results). Antibodies other than 101/I do not react to any extent with HBsAg. On the other hand, antibodies specific for WHsAg could react to a slight extent with GSHsAg, depending on the analytical assay used. For example, site IV and V antibodies react poorly with GSHsAg and exhibit much greater specificity for WHsAg than for GSHsAg. This is demonstrated in the liquidphase RIP, where antigenic competition is measured against a single antibody species (Fig. 2B) . Low-level reactivity of these antibodies with GSHsAg is also apparent in site-specific immunoadsorbent systems (Fig. 2B) . In contrast, absolute specificity of these antibodies for WHsAg is suggested by RIA with site-specific probes (Fig. 2B) . Of the antibodies demonstrating significant cross-reactivity with WHsAg and GSHsAg, monoclonal antibodies 3/II and 14/IT reacted preferentially with WHsAg in competition RIP, and both mapped to site II. In comparison, WHsAg-defined antibodies 19/III and 172/III preferred GSHsAg to WHsAg, and both mapped to site III ( Fig. 2A and B) . Therefore, competitive antibody mapping confirmed the presence of at least two cross-reactive domains between WHsAg and GSHsAg that were suggested initially by heteroplicity in antigen competition assays (4) . The reason why a subset of site III antibodies preferentially reacts with a heterologous antigen in the liquid-phase system is not clear at present.
Antigenic relatedness among hepadnavirus surface antigens requires at least some degree of homology at the level of DNA and amino acid sequences. WHsAg and HBsAg share up to 78% gene sequence homology and nearly 60% homology in their predicted amino acid sequences (6); however, there is somewhat less overall homology suggested by shared tryptic peptides (5, 11) . This is because the latter technique gives a minimum estimate of structural relatedness when compared to sequencing data. The antigenic relationships between hepadnavirus surface antigens may correlate closely with the minimal estimates of structural homology derived from peptide maps. For example, WHsAg can be detected in commercial assays designed for HBsAg detection; however, the reactivity in the system is at considerably lower signal/noise ratios when compared with HBsAg (8, 20) . This indicates that cross-reactivity between the two surface antigen-antibody systems is not as extensive as the DNA and amino acid sequence homologies might predict. In fact, Werner et al. (30) found only 3 to 5% homology between hepatitis B virus and WHV DNA by using hybridization techniques and subsequently demonstrated very little in the way of cross-reactiv- 
15- Table 1 ). The data are further supported by immunocomplex mapping of WHsAg by RIA (Table 4) (5) may not be evident in WHsAg from our colony woodchucks, or it may reflect structural microheterogeneity unrelated to the presence or absence of specific antigenic determinants. Reciprocal antigen-antiserum absorption studies with WHsAg and GSHsAg and with nonhomologous WHsAg are required to further clarify these points. In any event, the present RIA systems will be useful in screening for WHsAg variants in other areas where WHV infection is endemic. The identification and isolation of potential variants lacking specific epitopes within sites defined by competitive antibody mapping will enable the definition of nonoverlapping epitopes within such sites.
The information concerning antigenic domains of WHsAg will be of value in further developing the WHV system as a model for hepatitis B virus-induced liver disease in humans. The results of the present study show the antigenic similarity of WHV used as a standard infectious pool by our laboratory (woodchuck no. 8) and the WHsAg used to prepare our standard vaccine (woodchuck no. 7) (i.e., MCABs were predefined and selected with WHsAg from woodchuck no. 8 and were used to map antigenic domains of WHsAg from woodchuck no. 7). The antibodies can be used to ascertain the presence and distribution of defined sites on the actual virion. This is important because only those determinants of the 22- (2, 19) .
